MEDx Successfully Hosts MSD Technology Symposium to Advance Frontiers in Bioanalysis

Mar 13, 2025 09:54 CST Updated 09:54

MSD

Pharmaceutical R&D and Manufacturer

Recently, the world's leading bioanalysisTechnology CompanyMeso Scale Discovery (MSD), well-known life science service providerUnivBioAndTechnical expert teams from multiple pharmaceutical companiesGather TogetherMEDx Translational Medicine Research (Suzhou) Co., Ltd., jointly organized a high-level technical exchange meeting. The conference focused on the cutting-edge technologies and innovative applications of the MSD detection platform, centered aroundLatest Development Trends in the Field of BioanalysisConduct in-depth discussions. The experts present jointly explored the MSD platform through technical analysis, case sharing, and cross-disciplinary exchanges.Biopharmaceutical R&D, Immunogenicity Analysis, PD Biomarker DetectionBreakthrough progress in fields such as ..., for the biopharmaceutical industryTechnology Upgrade and Collaborative InnovationProvided a whole new perspective.

The successful hosting of this technical exchange meeting not only promoted the in-depth application of the MSD platform in the field of bioanalysis but also further advancedMaijie Medicine's Close Collaboration with Industry Partners，Join hands to accelerate the innovative development of the biopharmaceutical industry!

At the exchange meeting,Dr. Xiaotian He, Senior Application Scientist at MSDIn-depth Analysis ofElectrochemiluminescence (ECL) Detection PlatformThe core technical principles and their widespread application value in the industry. He elaborated in detail on the platform'sHigh-Sensitivity Bioanalysis, Drug Development, and Precision Medicinein areas such as... and demonstrated its role asImportant Tool in BioanalysisUnique advantages.

MSD Platform Relying on ItsMoreHeavy Detection, High Sensitivity, Wide Dynamic RangeTechnical features such asPharmacodynamics (PD), Immunogenicity Assessment (ADA), Pharmacokinetics (PK) and Toxicology Studies, Cytokine Profiling, and Tumor Microenvironment Researchand has demonstrated broad applicability in multiple fields. Particularly inComplex Biomarker Detection and Mechanism of Drug Action AnalysisAspect, the platformPlaying an irreplaceable role.

Displayed on-sitePCase of Multi-factor Dynamic Monitoring of D-1/PD-L1 Pathway, further verifying the MSD platform inDevelopment of Tumor Immunotherapy DrugsThe key value. The experts present unanimously agreed that the platform's high sensitivity, multiplex detection capability, and stability provideAccelerateDevelopment of Novel Anticancer Drugs and Optimization of Precision Treatment StrategiesProvided strong technical support.

Subsequently,Dr. Deyu Zhao, Head of Majie Medical Protein/Bioanalysis CenterShared“Application of MSD Platform in Drug Development — Examples of Immunogenicity Analysis and Biomarker Detection”The report. He elaborated on how Majie Medicine fully leverages the technical advantages of the MSD platform inBiologicalDrug Safety Evaluation, Efficacy Research, Precision Medicine Testing...and other aspects, showcasing the professional strength of Mager Bioanalytical in the field of bioanalysis through multiple practical cases.

During this exchange, Dr. Zhao provided a detailed introduction to the innovative application achievements of MedJourney based on the MSD technology platform. By deeply exploring the high sensitivity and multiplex detection capabilities of the MSD platform, MedJourney has achieved key technological breakthroughs in drug immunogenicity analysis, dynamic monitoring of biomarkers, and preclinical/clinical research.

Immunogenicity Assessment: Precise Detection of Anti-Drug Antibody Risk, Optimization of Dosing Regimens

Dr. Zhao Bo mainly shared the insights from Maki Medicine inMedicineMaterial Immunogenicity AssessmentRich experience in: Currently, the company is targeting bispecific antibody drugs (PD-L1x CD 40), CAR-T drugs (B7-H3), CAR-NK drugs (5T4), CAR-T drugs (ADA) (CD19), CAR-T drugs (ADA) (CLDN18.2), and CAR-T drugs (CD7).Utilizing the high-throughput anti-drug antibody (ADA) detection function of the MSD platform, accurately identified the risk of anti-drug antibodies in different patient subgroups, and simultaneously monitored the dynamic changes of key pharmacodynamic biomarkers, thereby successfully optimizing the dosing regimen. These studies have accumulated extensive testing experience, providing reliable support for the cell and gene therapy (CGT) field.

PD Biomarker Testing: Technological Breakthroughs Enhance Precision in Drug Efficacy Evaluation

In addition,Maijie Medicine inPD (Pharmacodynamics) Biomarker Testing FieldHas also accumulated profound experience. Regarding the Bcl-2:BIM complex detection for Bcl-2 inhibitors, MedGen Laboratories has successfully established a method to evaluate the drug's inhibitory effect, and the results indicate that this detection method is effective.BatchThe intra-assay and inter-assay precision are both within acceptable limits.Within the scope, showing good repeatability。

Dr. Zhao Bo also introducedSHP2 Function and Mutation Analysis, pERK/Total ERK DetectionIn multiple cases, it was pointed out that Majie Medical performed well in the validation of these testing methodologies. Notably,Maijie Medicine's reagents and methods developed for detecting SHP2 inhibitor activity in PBMC have been granted an invention patent., further consolidating the company's leading position in this field. At the same time, the company alsoBased on MSD PlatformCompleted the development and validation of dozens of methods for detecting cytokines and biomarkers.Work, and use these methods to support the drug development of many pharmaceutical companies.

In summary, Majie Medicine relies on the MSD platform inBiomarker Testing, CGT-Related Cytokine Testing...has accumulated rich clinical experience in fields such as these, and has established systematic solutions. In the future, MEDx will continue to deepen...Precision BioanalysisResearch, providing efficient and precise testing support for drug development, and contributing to the arrival of a new era of precision medicine!

This technical exchange meeting not only deepened the participating experts' understanding ofMSD TechnologyA deeper understanding has also further promotedPharmaceutical Companies and MJDxIn-depth cooperation and exchange in cutting-edge bioanalytical technologies.In the future, Majie Medicine will continue to deeply cultivate.Bioanalysis, Precision Medicine, and Companion DiagnosticsIn core areas such as these, there is a continuous drive for technological innovation and breakthrough applications.Maijie Medicine looks forward to joining hands with industry partners to jointly promote the innovation of biopharmaceutical technologies, providing more precise and efficient testing solutions for patients worldwide, and advancing the arrival of a new era of precision medicine.

About MSD

Medx Translational Medicine Research (Suzhou) Co., Ltd. (hereinafter referred to as: Medx Medicine) was established in 2013, formerly known as QIAGEN Translational Medicine Research Center. As a leader in comprehensive diagnostic solutions, Medx Medicine has three core businesses: integrated translational medicine technical support for drug clinical transformation, companion diagnostic product (CDx) development, and medication guidance testing. Based on comprehensive technology platforms including genomics, proteomics, cytomics, pathology omics, big data, and AI, along with a top-tier product development team, a robust R&D process, and a comprehensive quality system (covering CAP, CNAS ISO 17025, ISO13485, GMP, GSP, etc.), Medx Medicine focuses on targeted therapy, immunotherapy, and cell/gene therapy. It empowers drug clinical transformation research and develops corresponding companion diagnostic products to support precision medication after drug approval. Medx Medicine has collaborated with over 400 innovative pharmaceutical companies and technology firms globally, developed and validated hundreds of biomarkers and methodologies, and supported hundreds of drug clinical trials. To date, more than 20 of its products have received regulatory approval in China, covering solid tumors and hematological malignancies, including the first JAK2-V617F mutation detection kit and a PDL-1 detection kit for immunotherapy approved in China; as well as 8 CE-certified products. Additionally, its immunohistochemistry digital pathology image processing software has successfully obtained a Class II medical device registration certificate. Meanwhile, Medx Medicine has over 40 CDx/IVD products in its pipeline, with 10 currently undergoing clinical trials. Based on its unique integrated business model, Medx Medicine has rapidly grown into an innovative enterprise in China’s companion diagnostic solutions sector, addressing the pain points of innovative drug development and patient access to medications, and promoting precision medicine.